Last edition
News about "T-Cell Engagers"
Orum Therapeutics Appoints Dr Chad May as Chief Scientific Officer
Orum Therapeutics has appointed Dr Chad May, PhD, as Chief Scientific Officer (CSO), who brings over two decades of oncology and immunology research experience to advance the company’s degrader-antibody conjugate platform and pipeline of next-generation therapies.
T-cell Engagers | 05/01/2026 | By News Bureau
Harbour BioMed, AstraZeneca Advance Next-Gen Oncology Biotherapeutics Collaboration
Harbour BioMed has announced an update on the advancement of its global strategic collaboration with AstraZeneca to discover and develop next-generation biotherapeutics in oncology, including antibody-drug conjugates (ADCs) and T cell engagers.
T Cell Engagers | 24/11/2025 | By Dineshwori | 157
WuXi Biologics Signs Deal with Candid Therapeutics to Boost Trispecific T-cell Engager
Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal multispecific antibody platform WuXiBody.
T-cell Engagers | 07/01/2025 | By Aishwarya | 346
Boehringer Ingelheim Inks Second Pact with 3T Biosciences to Develop Cancer Immunotherapies
This second research partnership with 3T builds on the successful completion of the initial research partnership announced last year by the two companies.
T-Cell Engagers | 05/01/2024 | By Manvi | 544
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy